BUDGET
Proposes INR 100 billion outlay for Biopharma SHAKTI for 5 years
This story was originally published at 17:37 IST on 1 February 2026
Register to read our real-time news.Informist, Sunday, Feb. 1, 2026
Please click here to read all liners published on this story
--BUDGET: To scale mfg in bio pharma shakti
--BUDGET: Aim to develop India as global pharma manufacturing hub
--BUDGET: Propose INR 100 bln under biopharma shakti for 5 yrs
--BUDGET: To strengthen central drug standard organisation
--BUDGET: Bio pharma shakti will build ecosystem for mfg of biologics
--BUDGET: To build 3 new pharma institutions under bio pharma shakti plan
NEW DELHI – The Union Budget for 2026-27 (Apr-Mar) proposed an outlay of INR 100 billion over the next five years for Biopharma SHAKTI to position India as a global biopharma manufacturing hub. Biopharma SHAKTI is expanded as Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation.
"This will build the ecosystem for domestic production of biologics and biosimilars," Finance Minister Nirmala Sitharaman said in her Budget speech Sunday. She noted that India has been observing a growing burden of non-communicable diseases such as diabetes, cancer, and autoimmune disorders, making biologic medicines critical for improving longevity and quality of life at affordable costs.
Under Biopharma SHAKTI, the government will set up a biopharma-focused network, including three new National Institutes of Pharmaceutical Education and Research, while upgrading seven existing ones. The programme will also create a network of over 1,000 accredited clinical trial sites across the country.
"We propose to strengthen the Central Drugs Standard Control Organisation to meet global standards and approval timeframes through a dedicated scientific review cadre and specialists," Sitharaman said.
Shares of some pharmaceutical stocks surged after Sitharaman announced a higher Budget allocation in FY27 for the enhancement and development of healthcare facilities in India. Max Healthcare Institute was the top gainer in the Nifty 50 index, rising over 3%, followed by Sun Pharmaceutical Industries and Apollo Hospital Enterprises, which was up around 1?ch. Global Health rose over 6% and was among the top gainers in the Nifty 500 index. End
Reported by Afra Abubacker
Edited by Tanima Banerjee
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
